Latest News
Keep up to date with the latest news and announcements from Theragnostics
Developing radionuclide PARP inhibitors – MedNous Article
November 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference
November 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics
September 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research Programme
June 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership Recognition
May 7, 2020Theragnostics attending PSMA Masterclass – London
March 5, 2020Theragnostics attending JPM in San Francisco
January 13, 2020Theragnostics Expands Team with Significant Appointments
January 10, 2020Theragnostics strengthens leadership team with two key appointments
November 13, 2019News Archive
Developing radionuclide PARP inhibitors – MedNous Article
November 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference
November 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics
September 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research Programme
June 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership Recognition
May 7, 2020Theragnostics attending PSMA Masterclass – London
March 5, 2020Theragnostics attending JPM in San Francisco
January 13, 2020Theragnostics Expands Team with Significant Appointments
January 10, 2020News Archive